Paciente con debilidad aguda de hemicuerpo izquierdo
Palabras clave:
síndrome de Guillain-Barré, accidente cerebrovascular, paresia, anamnesis
Resumen
Es común que la brusca debilidad de hemicuerpo izquierdo, sobre todo en pacientes añosos y portadores de factores de riesgo cardiovascular, sea debida a un ictus, como causa etiológica.
Se presenta caso de mujer de 79 años que consultó por brusca debilidad de hemicuerpo izquierdo. Al examen físico se constata cuadriparesia a predominio de miembros izquierdos, con hipotonía e hiporreflexia. Luego de estudios pertinentes se confirma un síndrome de Guillain Barré, que mejoró con infusiones de inmunoglobulina humana.
Citas
1. Szmidel M, Ma H, Phan T. Use of the phrase “pyramidal weakness” within the past 100 years. BMJ Neurol Open [Internet]. 2024 [cited 2025 Mar 17];6(1):e000580. Available from: https://doi.org/10.1136/bmjno-2023-000580
2. Castle-Kirszbaum M, Goldschlager T. Pyramidal weakness: Is it time to retire the term? Clin Anat [Internet]. 2021 [cited 2025 Mar 17];34(3):478–82. Available from: https://pubmed.ncbi.nlm.nih.gov/33347647 Subscription required
3. Zedde M, Grisendi I, Pezzella FR, Napoli M, Moratti C, Valzania F, Pascarella R. Acute onset quadriplegia and stroke: Look at the brainstem, look at the midline. J Clin Med [Internet]. 2022 [cited 2025 Mar 17];11 (23):7205. Available from: https://doi.org/10.3390/jcm11237205
4. Cerezo S, Expósito J, Carrera L, Natera D, Nascimento A, Ortez C. Polineuropatías inmunomediadas. Medicina (Buenos Aires) [Internet]. 2025 [citado 17 Oct 2025];85(Supl. IV):41–6. Disponible en: https://www.medicinabuenosaires.com/revistas/vol85-25/s4/41s4.pdf
5. Hernández-Jardón CH, Velázquez-Pérez L. Aspectos epidemiológicos y clínicos del síndrome de Guillain-Baré, 2012-2022. Rev Med Inst Mex Seguro Soc [Internet]. 2024 [citado 17 Oct 2025];62(6):e6119. Disponible en: https://doi.org/10.5281/zenodo.13306747
6. Rałowska-Gmoch W, Koszewicz M, Łabuz-Roszak B, Budrewicz S, Dziadkowiak E. Diagnostic criteria and therapeutic implications of rapid-onset demyelinating polyneuropathies. Exp Mol Pathol [Internet]. 2024 [cited 2025 Mar 17];140:104942. Available from: https://doi.org/10.1016/j.yexmp.2024.104942
7. Jiao S, Li M, Zhi J, Yu Z, Cheng X, Gong Z. Guillain-Barré syndrome following brainstem infarction: a case report and pathophysiological hypothesis. Front Immunol [Internet]. 2025 [cited 2025 Oct 17];16:1610219. Available from: https://pubmed.ncbi.nlm.nih.gov/40969751
8. Guo F, Yao QY, Wu XH, Guo HX, Su XL, Zhou JF, et al. Clinical characteristics of Guillain-Barré syndrome in Shenzhen: a retrospective study. BMC Neurol [Internet]. 2025 [cited 2025 Sept 17];25(1):72. Available from: https://doi.org/10.1186/s12883-025-04061-3
9. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev [Internet]. 2014 [cited 2025 Mar 17];2014(9):CD002063. Available from: https://pubmed.ncbi.nlm.nih.gov/25238327
10. Wiegers EJA, Jacobs BC. New insights in the immune treatment of Guillain–Barré syndrome. Curr Opin Neurol [Internet]. 2025 [cited 2025 Nov 2];38(5):471–7. Available from: https://doi.org/10.1097/WCO.0000000000001408
2. Castle-Kirszbaum M, Goldschlager T. Pyramidal weakness: Is it time to retire the term? Clin Anat [Internet]. 2021 [cited 2025 Mar 17];34(3):478–82. Available from: https://pubmed.ncbi.nlm.nih.gov/33347647 Subscription required
3. Zedde M, Grisendi I, Pezzella FR, Napoli M, Moratti C, Valzania F, Pascarella R. Acute onset quadriplegia and stroke: Look at the brainstem, look at the midline. J Clin Med [Internet]. 2022 [cited 2025 Mar 17];11 (23):7205. Available from: https://doi.org/10.3390/jcm11237205
4. Cerezo S, Expósito J, Carrera L, Natera D, Nascimento A, Ortez C. Polineuropatías inmunomediadas. Medicina (Buenos Aires) [Internet]. 2025 [citado 17 Oct 2025];85(Supl. IV):41–6. Disponible en: https://www.medicinabuenosaires.com/revistas/vol85-25/s4/41s4.pdf
5. Hernández-Jardón CH, Velázquez-Pérez L. Aspectos epidemiológicos y clínicos del síndrome de Guillain-Baré, 2012-2022. Rev Med Inst Mex Seguro Soc [Internet]. 2024 [citado 17 Oct 2025];62(6):e6119. Disponible en: https://doi.org/10.5281/zenodo.13306747
6. Rałowska-Gmoch W, Koszewicz M, Łabuz-Roszak B, Budrewicz S, Dziadkowiak E. Diagnostic criteria and therapeutic implications of rapid-onset demyelinating polyneuropathies. Exp Mol Pathol [Internet]. 2024 [cited 2025 Mar 17];140:104942. Available from: https://doi.org/10.1016/j.yexmp.2024.104942
7. Jiao S, Li M, Zhi J, Yu Z, Cheng X, Gong Z. Guillain-Barré syndrome following brainstem infarction: a case report and pathophysiological hypothesis. Front Immunol [Internet]. 2025 [cited 2025 Oct 17];16:1610219. Available from: https://pubmed.ncbi.nlm.nih.gov/40969751
8. Guo F, Yao QY, Wu XH, Guo HX, Su XL, Zhou JF, et al. Clinical characteristics of Guillain-Barré syndrome in Shenzhen: a retrospective study. BMC Neurol [Internet]. 2025 [cited 2025 Sept 17];25(1):72. Available from: https://doi.org/10.1186/s12883-025-04061-3
9. Hughes RAC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev [Internet]. 2014 [cited 2025 Mar 17];2014(9):CD002063. Available from: https://pubmed.ncbi.nlm.nih.gov/25238327
10. Wiegers EJA, Jacobs BC. New insights in the immune treatment of Guillain–Barré syndrome. Curr Opin Neurol [Internet]. 2025 [cited 2025 Nov 2];38(5):471–7. Available from: https://doi.org/10.1097/WCO.0000000000001408
